
|Articles|June 13, 2008
Allergan to cash in on eyelash stimulant effect of glaucoma drug
Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Macular laser picks up speed: The technology accelerating retinal therapies
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
4
FLORetina 2025: Enrico Borrelli on reframing retinal disease through the lens of choroidal health
5













































